What GENEWIZ does

GENEWIZ, operating as a subsidiary of Azenta Life Sciences, is a multi-platform genomics contract research organization headquartered in South Plainfield, New Jersey. The company delivers a comprehensive suite of services spanning next-generation sequencing (NGS) on Illumina, PacBio, and Oxford Nanopore platforms; Sanger sequencing; single-cell sequencing as one of three exclusive 10x Genomics Global Clinical Research Organizations; gene synthesis and oligo production; plasmid DNA preparation; recombinant antibody and viral vector (AAV, lentivirus) production; and proteomics via Olink and Alamar NULISA. Its proprietary genoTYPER-NEXT assay enables high-throughput CRISPR validation at <1% allele frequency and up to 10,000 samples per run.

The company operates a hybrid go-to-market model: a self-serve CLIMS web portal enables product-led growth for unit-priced offerings such as Colony-EZ ($19.99/sample), PCR-EZ, Plasmid-EZ, Sanger-EZ, and Amplicon-EZ, while enterprise pharmaceutical, biotech, and clinical laboratory customers engage through dedicated Ph.D.-led quote processes and GLP/CLIA/CAP-compliant multi-year contracts. Physical sample logistics are a notable differentiator, with 1,800+ dropbox locations, 2,000+ pickup times, and six overnight sequencing laboratories enabling same-day or next-morning 8 AM turnaround in select US regions.

Revenue is generated transactionally per sample or per project, with custom project pricing for clinical and regulated services. The customer base spans pharmaceutical and biotechnology companies, academic and government research institutions, and clinical and diagnostic laboratories, served globally through regional offices in the US, UK/Europe, China, and Japan with multilingual portal support. No customer logos or revenue figures are publicly disclosed.

Name

GENEWIZ

Legal name

GENEWIZ from Azenta Life Sciences

Website

https://genewiz.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

501–1,000 employees

Short description

GENEWIZ, a subsidiary of Azenta Life Sciences, is a multi-platform genomics CRO offering NGS, Sanger sequencing, gene synthesis, viral vector production, and proteomics services to pharmaceutical, academic, and clinical laboratory customers globally via self-serve and enterprise channels.

Ownership category

akta.pro rank

Product category

Genomics Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industry

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

Keywords

• Next generation sequencing
• Sanger sequencing services
• Gene synthesis services
• Oligo synthesis
• Plasmid DNA preparation

Headquarters

HQ city

Plainfield

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Sequencing Services: Core revenue from next-generation sequencing (NGS), Sanger sequencing, and long-read sequencing services. Customers submit biological samples (DNA, RNA, cells, tissue) and receive sequencing data and analysis reports. Revenue is transaction-based per sample or per project.
2. Gene Synthesis and Molecular Biology Services: Revenue from gene synthesis, oligo synthesis, DNA plasmid preparation, recombinant antibody production, and viral vector packaging (AAV, lentivirus). Customers purchase custom synthetic DNA constructs and related molecular biology services on a per-order basis.
3. Clinical and Regulated Services: GLP-compliant services, CLIA-certified clinical whole exome and genome sequencing, and regulated environment Sanger sequencing for preclinical and clinical trial support. Revenue generated per project or contract basis for pharma and biotech clients.
4. Proteomics Services: Revenue from Olink proteomics and Alamar NULISA proteomics services, offering protein biomarker analysis using proximity extension assay technology.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

GENEWIZ is a multi-platform genomics contract research organization that provides next-generation sequencing (NGS), Sanger sequencing, gene synthesis, oligo synthesis, plasmid DNA preparation, recombinant antibody and viral vector (AAV and lentivirus) production, and proteomics services. Customers submit biological samples and receive sequencing data, synthetic DNA constructs, viral vectors, antibodies, or protein biomarker results on a transaction or quote-based fee for use.

Product overview

GENEWIZ from Azenta Life Sciences is a multi-service genomics contract research organization offering a comprehensive portfolio of sequencing and synthesis services. The core service platform consists of Next Generation Sequencing (including transcriptomics such as RNA-Seq, Lightning Fast RNA-Seq, Single-Cell RNA-Seq, and Spatial Transcriptomics; genomics including Amplicon Sequencing, Whole Genome Sequencing, and Exome Sequencing; and applications such as AAV Gene Therapy Sequencing, Epigenomics, Metagenomics, and Immunogenomics), Sanger Sequencing (including Sanger-EZ, AAV-ITR Sanger Sequencing, Direct Colony Sequencing, and Fragment Analysis), Gene Synthesis (including Gene Fragments, Gene Synthesis, Synthetic DNA Libraries, Single-Stranded DNA, and the integrated Gene to Discovery pipeline), and Plasmid & Amplicon Sequencing (including Plasmid-EZ, Colony-EZ, PCR-EZ, and Amplicon-EZ). Supporting services include Oligo Synthesis (Overnight DNA Oligos, Modified DNA and RNA Oligos, Custom RNA Oligos), Plasmid DNA Preparation (Standard, Targeted Yield, and AAV Plasmid Preparation), Translational and Clinical Services (Clinical Whole Exome/Genome Sequencing, Regulated Environment Sanger Sequencing, GLP-Compliant Services, CLIA Integration Site Analysis, and Microarray Solutions), Antibody & Viral Production (Antibody Production, AAV Packaging, Lentivirus Packaging), and Proteomics Services (Olink and NULISA). The company also offers specialized solutions including High-Throughput Genotyping (genoTYPER-NEXT) for CRISPR validation, TargetGxOne Custom Gene Panels, and OncoGxOne Discovery Cancer Panels. GENEWIZ operates as a 10x Genomics Certified Service Provider and one of three exclusive 10x Genomics Global Clinical Research Organizations, utilizing platforms including Illumina NovaSeq, PacBio Revio, and 10x Genomics Chromium X for single-cell sequencing workflows.

Differentiator

Problem solved

Functional benefit

Brands

• Plasmid-EZ: Whole plasmid sequencing service starting from purified plasmid DNA
• Colony-EZ
• PCR-EZ
• Amplicon-EZ
• Sanger-EZ
• genoTYPER-NEXT
• TargetGxOne
• OncoGxOne

Products and services

• Next Generation Sequencing (NGS) Services Multi-platform next-generation sequencing services using Illumina (NovaSeq X Plus, NovaSeq 6000, MiSeq), PacBio (Revio, Sequel), Oxford Nanopore, and 10x Genomics platforms, spanning RNA-Seq, single-cell RNA-Seq, spatial transcriptomics, whole genome sequencing, exome sequencing, amplicon sequencing, AAV gene therapy sequencing, epigenomics, metagenomics, and immunogenomics for academic, pharmaceutical, biotechnology, and clinical researchers.
• High-Throughput Genotyping (genoTYPER-NEXT) Proprietary NGS-based high-throughput genotyping assay for CRISPR validation and screening engineered cell lines, supporting detection of less than 1% allele frequency with full INDEL resolution, frameshift analysis, and automated screening of up to 10,000 samples per run. Targeted at pharmaceutical, biotechnology, and academic genome editing researchers.
• Sanger Sequencing Services Capillary Sanger sequencing services including the prepaid Sanger-EZ solution, AAV-ITR Sanger Sequencing for AAV inverted terminal repeat verification, Direct Colony Sequencing from bacterial colonies without plasmid purification, and Fragment Analysis for genotyping and mutation detection. Targeted at molecular biology and genomics researchers.
• Gene Synthesis Services Custom synthetic DNA services including Gene Fragments, full-length Gene Synthesis, pooled Synthetic DNA Libraries for high-throughput screening, and Single-Stranded DNA synthesis, used by researchers to obtain custom DNA sequences for cloning, expression, library construction, and therapeutic development.
• Plasmid & Amplicon Sequencing Services Fast turnaround whole plasmid and amplicon sequencing services including Plasmid-EZ (whole plasmid sequencing from purified plasmid DNA), Colony-EZ (sequencing directly from bacterial colonies with in-house plasmid isolation), PCR-EZ (long-read PCR product sequencing for 500bp to 25kb amplicons with same- or next-day results), and Amplicon-EZ (Illumina short-read sequencing for purified PCR products 150-600bp). Targeted at molecular biology researchers needing rapid clone verification.
• Oligo Synthesis Services DNA and RNA oligonucleotide synthesis services covering Overnight DNA Oligos (15-60 bases with 1-2 business day delivery), Modified DNA and RNA Oligos (with chemical modifications and purifications), Custom RNA Oligos (including LNA and 2-O-Me-RNA modified nucleotides), and Oligos Retained for Sanger Sequencing where oligos are retained on-site for downstream sequencing orders. Targeted at molecular biology and genomics researchers.
• Plasmid DNA Preparation Services Plasmid DNA preparation services including Standard Plasmid DNA Prep, high-yield Targeted Yield Plasmid DNA Prep, and AAV Plasmid Preparation specialized for downstream AAV vector production, providing research-grade and AAV-production-grade plasmid material for researchers and gene therapy developers.
• Gene to Discovery Workflow (Gene to Antibody / Lentivirus / AAV / RNA) Integrated gene-to-deliverable workflow connecting gene synthesis to downstream biological deliverables: Gene to Antibody (recombinant antibody production), Gene to Lentivirus (lentiviral vector packaging), Gene to AAV (AAV vector packaging), and Gene to RNA (custom mRNA synthesis). Targeted at cell and gene therapy developers, antibody discovery researchers, and RNA therapeutics programs.
• Antibody & Viral Production (AAV Packaging, Lentivirus Packaging, Antibody Production) Recombinant Antibody Production, AAV Packaging (adeno-associated virus vector packaging for gene therapy research), and Lentivirus Packaging (for stable gene delivery applications), serving gene therapy developers, antibody discovery researchers, and cell engineering programs.
• Translational and Clinical Services (CLIA / GLP) Regulated clinical and preclinical research services including CLIA-certified Clinical Whole Exome and Whole Genome Sequencing, Regulated Environment Sanger Sequencing and Variant Confirmation, GLP-Compliant Services for regulatory submissions, CLIA Integration Site Analysis for cell and gene therapy, and Microarray Solutions for translational and clinical research. Targeted at clinical labs, pharma, and biotech conducting regulated research.
• Proteomics Services (Olink, Alamar NULISA) Proteomics services offering Olink proximity extension assay (PEA) technology for high-multiplex protein biomarker analysis across multiple disease areas, and Alamar NULISA proximity ligation methodology for ultrasensitive protein biomarker detection, used by researchers for biomarker discovery and protein analysis.
• Targeted Resequencing Panels (TargetGxOne, OncoGxOne, GENEWIZ Pan-Cancer Panel) Targeted resequencing panel services for biomarker discovery and research stratification: TargetGxOne Custom Gene Panels using Agilent SureSelect chemistry or proprietary amplicon approach, OncoGxOne Discovery Cancer Panels covering 150-400 genes across 19 organ-specific cancer panels, and GENEWIZ Pan-Cancer Panel covering all exons for 634 tumor suppressors and oncogenes. Targeted at oncology and translational researchers.

Quantifiable outcome

• Up to 10,000 samples per run with genoTYPER-NEXT for CRISPR validation
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered core.

• 10x GenomicscoreTechnology or IntegrationGENEWIZ is one of three exclusive 10x Genomics Global Clinical Research Organizations (CROs), certified to deliver single-cell sequencing services using 10x Genomics Chromium X platform. The partnership provides access to 10x's microfluidic single-cell technology for transcriptomics, epigenomics (ATAC-Seq), immune profiling, and multiomics applications.
• IlluminacoreTechnology or IntegrationIllumina certified service provider. GENEWIZ operates Illumina NovaSeq X Plus, NovaSeq 6000, and MiSeq platforms for short-read sequencing services including whole genome, exome, targeted, RNA-Seq, and single-cell sequencing.
• PacBiocoreTechnology or IntegrationCertified PacBio service provider. GENEWIZ operates PacBio Revio and Sequel systems for long-read SMRT sequencing including HiFi reads, amplicon sequencing, and Iso-Seq transcriptomics.
• Azenta Life Sciences (Parent Company)coreOthersGENEWIZ is a brand of Azenta Life Sciences, a global life sciences company providing sample lifecycle management and analytics solutions. GENEWIZ operates as the genomics services division of Azenta, which also offers automated sample storage (BioBank) and sample intelligence solutions.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Others

• Azenta Life Sciences: Azenta is GENEWIZ's parent company and provides sample storage, biobanking, and sample intelligence solutions — adjacent infrastructure that bundles with GENEWIZ genomics services for end-to-end sample lifecycle offerings.
• Illumina: Illumina is the dominant short-read sequencing platform provider whose instruments and reagents GENEWIZ uses operationally; Illumina-certified service providers like GENEWIZ sit in Illumina's installed-base ecosystem.

Direct peers

• Macrogen: Macrogen is a global sequencing services CRO headquartered in Korea offering NGS, Sanger, and microarray services with strong Asia-Pacific presence, overlapping significantly with GENEWIZ's global services portfolio.
• Integrated DNA Technologies (IDT): IDT (owned by Danaher) provides custom oligonucleotides, gene synthesis, and Sanger/NGS services directly overlapping with GENEWIZ's oligo synthesis, gene synthesis, and Sanger-EZ offerings.
• Eurofins Genomics: Eurofins Genomics is a global genomics services provider offering Sanger, NGS, gene synthesis, and qPCR services — directly competing with GENEWIZ across the same product lines and customer segments.
• BGI Genomics / MGI Tech: BGI/MGI provides global NGS services and DNBSEQ sequencing platforms that overlap with GENEWIZ's multi-platform sequencing services, particularly in the Asia-Pacific market where GENEWIZ also operates.
• Twist Bioscience: Twist Bioscience is a direct competitor in synthetic DNA/gene synthesis and offers NGS target enrichment panels and antibody discovery services that overlap with GENEWIZ's gene synthesis and NGS workflows.

Emerging players

• New England Biolabs: New England Biolabs is expanding into genomics services and RNA therapeutics manufacturing and is mentioned in industry context alongside GENEWIZ as a competing/peer CMO/CDMO in the RNA therapeutics supply chain.

Broad incumbents

• QIAGEN: QIAGEN provides sample technologies, molecular diagnostics, and NGS-related consumables/services that are adjacent to GENEWIZ's molecular biology and clinical sequencing offerings as part of a much broader portfolio.
• Charles River Laboratories: Charles River is a large CRO offering preclinical and clinical research services including genomics, cell therapy, and gene therapy support that overlaps with GENEWIZ's regulated services but at much broader scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/genewiz
• Facebookfacebook.com/gene.wiz
• LinkedInlinkedin.com/company/genewiz

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GENEWIZ